Mission BioCapital Announces $275 Million Fund V
Mission BioCapital V LP is more than double the size of the firms prior fund.
- Mission BioCapital V LP is more than double the size of the firms prior fund.
- Our team empowers exceptional biotech entrepreneurs from all walks of life, said Peter D. Parker, co-founder and managing general partner of Mission BioCapital.
- Mission BioCapital has already funded seven companies from the new fund, including four where it has played a co-founder role ARase Therapeutics, Arclight Therapeutics LLC, Jupiter Bioventures, and Telo Therapeutics.
- Prior to joining Mission BioCapital, Dr. Tregay served as founder, president and chief executive officer of FORMA Therapeutics (NASDAQ: FMTX), raising $875 million in non-dilutive funding alongside venture investments of $44 million and advancing seven clinical drug candidates.